出处
《中国中西医结合肾病杂志》
2001年第6期367-369,共3页
Chinese Journal of Integrated Traditional and Western Nephrology
基金
卫生部临床学科基金重点资助项目 (No .970 40 2 2 8)
中山医科大学"2 11"工程 (NO .9815 1)
瑞典KarolinskaInstitute合作基金
参考文献11
-
1Foley RN, Parfrey PS, Hamett JD, et al. The impact of anemia on cardiomyopathy,morbity and mortality in endstage renal disease. Am J Kidney Dis, 1996, 28: 53-61.
-
2Foley RN, Parfrey PS. Complications of long-term dialysis: Cardiovascular complications and cardiac risk factor interventions, in Brown E and parfrey P: Complications of Long Term Dialysis, Oxford NY, Oxford University press,1999,29-52.
-
3Locatelli F,Conte F, Marcelli D. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity-The experience of the Lombardy Dialysis Registry. Nephrol Dial Transpl,1998,13:1642-1644.
-
4Ma JZ, Ebben J, Xia H, et al. Hematocrit levels and associated mortality in hemodialysis patients. J Am Soc Nephrol, 1999, 10: 610-619.
-
5Madore F, Lowrie EG, Brugnara NL, et al. Anemia in hemodialysis patients: Variable affecting this outcome predictor. J Am Soc Nephrol, 1997,8:1921-1929.
-
6Kratz A, Lewandroski KB. Case records of the Massachusetts general hospital. Weekly clinicopathological exercises. Normal reference laboratory values. N Engl J Med, 1998,339:1063-1072.
-
7Foley RN, Parfrey PS, Kent GM, et al. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int, 1998,54:1720-1725.
-
8Besarab A, Bolton K, Browne JK, et al. The effects of normal as compared with low hemotocrit values in patients with cardiac disease who are reciving hemodialysis and epoetin. N Engl J Med, 1998,339: 584-590.
-
9Portoles J,Torralbo A,Martin P,et al. Cardiocascular effects os recombinant human erythropoietin in predialysis patients. Am J Kidney Dis, 1997,29:541-548.
-
10Eschbach JW,NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis, 1997, (Suppl 3)30:192-240.
同被引文献8
-
1王海燕 王梅 左力.慢性肾脏病及透析的临床实践指南[M].北京:人民卫生出版社,2004.289-292.
-
2张文南.血液病诊断及疗效标准[M].天津:天津科学技术出版社,1991,1..
-
3Daurgidas J T.Rapid methods of estimating Kt/V: three formulas compared[J]. ASAIO Trans, 1990,36(3):M362.?A
-
4Daurgidas J T Rapid methods of estimating Kt / V :three formulas eompared[J]. ASAIO Trans, 1990,36(3)::M362.
-
5苏颖,李学旺,余学清,王质刚,冯学亮,刘先蓉.基因重组人红细胞生成素注射液治疗肾性贫血的多中心临床研究[J].中国医学科学院学报,2001,23(3):232-236. 被引量：15
-
6方永顺.人参与黄芪配伍免疫作用的药理研究[J].中医药学刊,2002,20(4):471-471. 被引量：44
-
7张春香.血液透析并发贫血的中医治疗[J].山西中医学院学报,2002,3(3):36-36. 被引量：1
-
8杨莉,王梅,潘缉圣,陈香美,李文歌,王笑云,赵卫红,余香宝,毛惠娟,胡建明,顾勇,薛骏,施雪枫,姚建,王一新,张政.静脉用右旋糖酐氢氧化铁注射液治疗血液透析患者肾性贫血的随机及多中心对照临床研究[J].中华肾脏病杂志,2003,19(2):85-89. 被引量：65
二级引证文献4
-
1王海花,李娟,杨德花.古方今用——归脾丸[J].中国医药导报,2006,3(18):104-105. 被引量：2
-
2马俊杰,张以来.基于归脾丸对MHD CKD贫血患者微炎症状态调节探讨“培土生血”内涵[J].世界科学技术-中医药现代化,2014,16(3):634-637. 被引量：10
-
3孙杰,马俊杰,张以来,魏善斋.归脾丸改善血液透析患者贫血及对炎症因子的影响[J].南京中医药大学学报,2016,32(1):14-16. 被引量：8
-
4李静,马雷雷,纪越,付宝慧,刘瑞琪,杨洪涛.从肾性贫血发生机制的新进展探讨中医药研究肾性贫血的潜在靶点[J].中国中西医结合肾病杂志,2021,22(10):932-934. 被引量：4
-
1代玲俐,欧阳晓俊,陈吉海,卞茸文.2型糖尿病患者注射利拉鲁肽后出现房室传导阻滞一例报道[J].中国糖尿病杂志,2015,23(12):1121-1123. 被引量：2
-
2孟华.2型糖尿病106例动态心电图分析[J].山东医药,2011,51(33):108-108. 被引量：3
-
3代建军.依那普利对急性心肌梗死患者左心功能及重塑过程的影响[J].中华综合医学,2002,3(5):421-422.
-
4黄斌雄.肥厚型心肌病伴左心室扩张的临床分析[J].上海医学,2002,25(10):661-662.
-
5林娜,郭晋祥.尿激酶溶栓治疗急性心肌梗死对心室功能的改善作用[J].华中医学杂志,2002,26(6):329-330. 被引量：1
-
6刘效平,胡引柱.一家族三代人同患原发性扩张型心肌病3例[J].山西医药杂志（下半月）,2008,37(3):196-196.
-
7张成国,牛红梅.西拉普利对急性心肌梗死患者左心功能及重塑过程的影响[J].基层医学论坛,2005,9(4):324-325.
-
8蒙艳,陈刚.^(131)I治疗老年甲亢合并心脏疾病患者临床疗效分析[J].中国医药导刊,2016,18(7):710-711. 被引量：5
-
9余康敏,王春友,陈鑫.急性胰腺炎合并心脏疾病的处理[J].华中医学杂志,2004,28(2):112-113.
-
10刘莹,鲁旭彦,苏静,李菲.高血压病合并心脏疾病的处理[J].现代康复,1999,3(10):1235-1235.
